Invest in the Bimek SLV now

The Revolution of Contraception

For decades medical science has been searching for a contraceptive method for men, but this research has not progressed beyond the condom and vasectomy. There are no reliable, as well as reversible, male contraceptive methods available.

Every year over 55 000 men across Germany, and about 60 million worldwide, undergo a vasectomy. As much as 10% of these men then opt for a reversal later on.

German inventor, Clemens Bimek, has successfully provided a revolutionary development with the Bimek spermatic duct valve (Bimek SLV), which is now fully developed and already patented internationally.

Reliable, easy to use, unique and sustainable, with regard to its materials and production – the Bimek SLV fulfils all the criteria of a modern contraceptive. The valve is attached to the spermatic duct and, when closed, prevents the release of sperm cells during ejaculation. The user is then sterile. He can, however, also change this whenever desired; the tiny valve can be opened and closed by the wearer.

With the aid of a small team of specialists and in coordination with a renowned clinic, the medical approval procedure has been initiated. At its current progress, the Bimek SLV will receive market approval by 2023 for the European market.

Established cooperation partners for medical devices will take over the distribution with a licence. Step by step, the product will be ready to launch on the international market. By 2025 investors will be able to receive a pay out of 3 to 5 times their original investment. The minimum investment is only 75 000€.

Become part of a new era in medical science and invest in the future of the contraceptives market.

Highlights

Unique: The finality of a vasectomy (male sterilisation) is no longer an issue, as the valve’s function can be switched on and off at will.

Simple: The valve is implanted during an outpatient surgery that lasts about 30 minutes. Opening and closing the Bimek SLV requires a simple flip of a switch that can be done from outside the skin of the scrotum.

Patented: The Bimek spermatic duct valve is registered internationally for patent approval and the medical approval process in Germany has already been initiated.

Scalable: The valve’s target group is the millions of men around the world, who’d prefer the Bimek SLV over a vasectomy.

Basic info

Financing round:
Series A (1 of 3 rounds)

Current required capital:
600 000 EUR for 20 % shares

Minimum investment:
75 000 EUR for 2,5 % shares

Project status:
Start of med. approval process

Sales launch:
Summer 2023

Patents and inventors

Lead investor PES Innovation AG (Switzerland) has been supporting the project for many years and since July 31, 1818 has held the patent for the US under patent No .: US 10,034,794 B2 “DEVICE FOR CONTRACEPTION FOR US BY A MAN”. Likewise, PES Innovation AG holds since 02.05.2018 alone the European Patent No. 3 128 965 “device for contraception for use in men”. Nationalization took place in the most important European countries. Older patents are no longer valid. Inventor of the Bimek SLV is Clemens Bimek (Switzerland).